A study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals’ RSV investigational vaccine based on viral proteins encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in infants.

StatusActive
Effective start/end date8/09/1915/11/20

Funding

  • GlaxoSmithKline